Hansoh Pharma Secures Dual NMPA Clinical Trial Approvals for HS-10522 Targeting Hypertension and Primary Aldosteronism

Bulletin Express04-29 20:43

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that the National Medical Products Administration (NMPA) of China has granted two Clinical Trial Approvals for HS-10522 tablets, the company’s self-developed Class 1 innovative drug.

The clearances authorize separate clinical studies evaluating HS-10522 for: 1. Treatment of uncontrolled hypertension (uHTN) 2. Treatment of primary aldosteronism (PA)

The approvals allow Hansoh Pharma to initiate formal clinical investigations in mainland China, advancing the compound into its next development phase for both cardiovascular and endocrine indications.

The Board of Directors disclosed the development in a voluntary announcement dated 29 April 2026. No additional financial details or trial timelines were provided in the statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100282380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100282380","market":"us","top_or_hot":-1,"title":"Hansoh Pharma Secures Dual NMPA Clinical Trial Approvals for HS-10522 Targeting Hypertension and Primary Aldosteronism","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that the National Medical Products Administration (NMPA) of China has granted two Clinical Trial Approvals for HS-10522 tablets, the company’s self-developed Class 1 innovative drug.</p>\n<p>The clearances authorize separate clinical studies evaluating HS-10522 for:  \n1. Treatment of uncontrolled hypertension (uHTN)  \n2. Treatment of primary aldosteronism (PA)</p>\n<p>The approvals allow Hansoh Pharma to initiate formal clinical investigations in mainland China, advancing the compound into its next development phase for both cardiovascular and endocrine indications.</p>\n<p>The Board of Directors disclosed the development in a voluntary announcement dated 29 April 2026. No additional financial details or trial timelines were provided in the statement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Secures Dual NMPA Clinical Trial Approvals for HS-10522 Targeting Hypertension and Primary Aldosteronism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Secures Dual NMPA Clinical Trial Approvals for HS-10522 Targeting Hypertension and Primary Aldosteronism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that the National Medical Products Administration (NMPA) of China has granted two Clinical Trial Approvals for HS-10522 tablets, the company’s self-developed Class 1 innovative drug.</p>\n<p>The clearances authorize separate clinical studies evaluating HS-10522 for:  \n1. Treatment of uncontrolled hypertension (uHTN)  \n2. Treatment of primary aldosteronism (PA)</p>\n<p>The approvals allow Hansoh Pharma to initiate formal clinical investigations in mainland China, advancing the compound into its next development phase for both cardiovascular and endocrine indications.</p>\n<p>The Board of Directors disclosed the development in a voluntary announcement dated 29 April 2026. No additional financial details or trial timelines were provided in the statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1100282380","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100282380","pubTimestamp":1777466639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that the National Medical Products Administration (NMPA) of China has granted two Clinical Trial Approvals for HS-10522 tablets,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"翰森制药针对高血压和原发性醛固酮增多症的HS-10522获得NMPA双临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that the National Medical Products Administration (NMPA) of China has granted two Clinical Trial Approvals for HS-10522 tablets, the company’s self-developed Class 1 innovative drug.\nThe clearances authorize separate clinical studies evaluating HS-10522 for:  \n1. Treatment of uncontrolled hypertension (uHTN)  \n2. Treatment of primary aldosteronism (PA)\nThe approvals allow Hansoh Pharma to initiate formal clinical investigations in mainland China, advancing the compound into its next development phase for both cardiovascular and endocrine indications.\nThe Board of Directors disclosed the development in a voluntary announcement dated 29 April 2026. No additional financial details or trial timelines were provided in the statement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100282380","isCrawlerRequest":true}